Literature DB >> 14582909

Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis.

M Krane1, M Griese.   

Abstract

Surfactant protein D (SP-D) interacts with Aspergillus fumigatus and is strongly increased in the lavage from animals with acute allergic reactions to the fungus, suggesting a central role for SP-D. As the course of cystic fibrosis (CF) is often complicated by an allergic bronchopulmonary aspergillosis (ABPA), the authors hypothesised that SP-D may also be increased in serum during an ABPA, potentially assisting in its diagnosis and follow-up. In 22 patients with CF (11 with ABPA, 11 matched without ABPA) and 19 control patients without a pulmonary disease, SP-D concentrations in serum were assessed by an enzyme immunoassay. Serum SP-D in CF patients (130 +/- 16 ng x mL(-1) (mean +/- SEM)) was significantly higher than in the controls without lung disease (66 +/- 8 ng x mL(-1)). During the whole ABPA-episode, SP-D level did not change significantly, despite large changes of total serum immunoglobulin E. There was a clear negative correlation between SP-D concentration and overall lung function, i.e. forced expiratory volume in one second and forced vital capacity. Serum level of surfactant protein D may be of value to follow pulmonary function and lung injury in cystic fibrosis patients. Surfactant protein D serum levels are not helpful for the diagnosis and follow-up of an allergic bronchopulmonary aspergillosis episode, contrary to what was expected from animal experiments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14582909     DOI: 10.1183/09031936.03.00060603

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

Review 1.  Innate immunity to Aspergillus species.

Authors:  Stacy J Park; Borna Mehrad
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

2.  Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis.

Authors:  Michael W Sims; Michael F Beers; Vivek N Ahya; Steven M Kawut; Karen D Sims; David J Lederer; Scott M Palmer; Keith Wille; Vibha N Lama; Pali D Shah; Jonathan B Orens; Sangeeta Bhorade; Maria Crespo; Ann Weinacker; Ejigayehu Demissie; Scarlett Bellamy; Jason D Christie; Lorraine B Ware
Journal:  Chest       Date:  2011-02-24       Impact factor: 9.410

Review 3.  Eosinophil-associated lung diseases. A cry for surfactant proteins A and D help?

Authors:  Julie G Ledford; Kenneth J Addison; Matthew W Foster; Loretta G Que
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

Review 4.  Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury.

Authors:  Patricia Silveyra; Joanna Floros
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

5.  Factors influencing the measurement of plasma/serum surfactant protein D levels by ELISA.

Authors:  Preston E Bratcher; Amit Gaggar
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

6.  Genetic Association With Pseudomonas aeruginosa Acquisition in Cystic Fibrosis: Influence of Surfactant Protein D and Mannose-Binding Lectin.

Authors:  Nasenien Nourkami-Tutdibi; Klemens Freitag; Michael Zemlin; Erol Tutdibi
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

7.  Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study.

Authors:  Don D Sin; Rochelle Leung; Wen Q Gan; Sf Paul Man
Journal:  BMC Pulm Med       Date:  2007-10-08       Impact factor: 3.317

Review 8.  Surfactant Protein D in Respiratory and Non-Respiratory Diseases.

Authors:  Grith L Sorensen
Journal:  Front Med (Lausanne)       Date:  2018-02-08

9.  Elevated plasma surfactant protein D (SP-D) levels and a direct correlation with anti-severe acute respiratory syndrome coronavirus-specific IgG antibody in SARS patients.

Authors:  Y P Wu; Z H Liu; R Wei; S D Pan; N Y Mao; B Chen; J J Han; F S Zhang; U Holmskov; Z L Xia; P G de Groot; K B M Reid; W B Xu; G L Sorensen
Journal:  Scand J Immunol       Date:  2009-06       Impact factor: 3.487

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.